---
document_datetime: 2025-03-25 16:51:25
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/agamree-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: agamree-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.8841953
conversion_datetime: 2025-12-28 00:08:40.736634
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## AGAMREE

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                         |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009              | Please refer to the Recommendations section above. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 16/01/2025                          |                                             | SmPC and PL                      | The SmPC sections 4.2 & 6.6 have been updated with the following additional information: Section 4.2: Administration of AGAMREE oral suspension via enteral feeding tube AGAMREE oral suspension may be administered through an |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                 |            |     |      | enteral feeding tube (see section 6.6). Section 6.6: Use with an enteral feeding tube: AGAMREE can be administered through an enteral feeding tube (12 - 24 fr) without modification or dilution of the usual prescribed dose. AGAMREE should not be mixed with the feeding formula or other products. Flushing the enteral feeding tube with a minimum of 20 ml of water before and after administration of AGAMREE should be performed. The PL has been updated accordingly.   |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/223/2 02404 | Periodic Safety Update EU Single assessment - vamorolone                                                                                                        | 28/11/2024 | n/a |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0005           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                               | 28/11/2024 | n/a |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0008           | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                   | 14/11/2024 | n/a |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0004           | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                       | 24/06/2024 |     | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0003/G         | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 28/05/2024 | n/a |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | material/reagent/intermediate - Minor to an approved test procedure                                                                                                    |            |     |      | starting changes   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|--------------------|
| IA/0002 | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                          | 09/05/2024 |     | SmPC |                    |
| IB/0001 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 26/02/2024 | n/a |      |                    |